Ryotaro Ohkuma

4PUBLICATIONS
45CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 27, 2026
Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

|Jan 06, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.

Isabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma

|Jan 23, 2024
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.

Masahiro Hosonuma, Yuya Hirasawa, Atsuo Kuramasu

|Jan 11, 2020
High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.

Ryotaro Ohkuma, Erica Yada, Shumpei Ishikawa

Pageof 1

Frequent Collaborators

3 joint publications

Satoshi Wada

2 joint publications

Kazuyuki Hamada

2 joint publications

Kiyoshi Yoshimura

1 joint publications

Junji Tsurutani